Genentech Collaborates with Immunocore to Co-develop IMC-C103C for MAGE-A4 (Melanoma-Associated Antigen A4)

Shots:

• Immunocore to receive $100M upfront plus milestone payment and has an option to license IMC-C103C or grant its full rights to Genentech. If not exercised option to license, Immunocore will receive milestones and royalties
• Immunocore will conduct clinical trial to evaluate IMC-C103C as a monothx or in combination with Tecentriq (atezolizumab), which will be initiated in H1’19
• IMC-C103C is a mAb, is being developed for targeting tumors expressing protein MAGE-A4 (Melanoma-Associated Antigen A4)

Click here to read full press release/ article | Ref: Immunocore| Image: Center for Health Journalism